Member Info for Soupdragon78

Also worth noting in the December presentation that it highlights the additional tests that were talked about and undertaken in the second half of last year.

'NXP002 outperformed perfenidone in both fibrotic (Col1a1 and fibronectin) & inflammatory (MCP-1, IL-6 & IL-8) IPF pathways across 6 patient donors.'

Thanks NFT's.

Just for my clarity...

is this the same placing you said would happen last July and didn't...

or the one you said would happen last September and didn't...

or the one you said would happen in December and didn't?

Thanks NFT's.

Just for my clarity is this the same placing you said would happen last July and didn't, or the one you said would happen last September and didn't, or the one you said would happen in December and didn't?

Thanks NFT's we know you sold out at 0.21p.

Hows AVCT going after you told us to buy at 135p?

Thanks NFT's we know you sold out at 0.21p.

Hows AVCT going after you told us to buy at 135p?

Thanks NFT's you've been saying that for the past year since you sold out at 0.21p

Hows AVCT doing since you said to buy at 135p?

Fx, I think it’s grainy because the USPTO only worked in paper until last year.

You said that last June NFT’s.

How’s Avacta doing after you said to buy at 135p?

Fx, take it as an opportunity to learn how to do basic research. All the info you need is in the link I gave.

It literally tells you where I got it FX, not sure why I need to spoon feed people.

Companies make documents for different purposes.

Certainly is legit fx.

Moneybags, it came from research. It’s not difficult to figure out where.

Lol.. actually not Fx

Hi NFTs, How's AVCT done since you told us to buy it at 135p?

I'm enjoying that this is being called the "Gooding Declaration"

https://shorturl.at/bhkqB

"Major licensee technical objections regarding viability of NXP002 as an inhaled therapy are now addressed..."

Hope so FX.

“… We expect the European grant to follow shortly, which will further support the Company's on-going partnering activities.”

Certainly helps to have the patents granted.

NXP002 now has approvals in US, Japan and EU.

On a positive note, the 'intention to grant' for the European Patent of NXP002 has now come through.

https://patentscope.wipo.int/search/en/detail.jsf?docId=EP328059213&_cid=P21-LS8UKP-85805-1

The thought behind it being a market maker holding the warrants is along the line of;

The warrants were issued as part of the fund raising last year. So the company raise an amount of cash up front, but don’t get the cash for the warrants till they’re exercised.

Typically this would be out of the companies control as to when it happens, but if they are held by a MM, there could be an agreement that they can be exercised at the company’s request as and when they needed the money.

So Peel (or another MM) hold the warrants and are exempt from notification.

NFX tell them when they need the monies released.

The MM then forward sells into the market, raising the cash to give to the company.

The warrants are later exercised and the MM has the shares to hand again without having to declare a holding.

For me it’s more expecting to see an ‘exercise of warrants’ rns.

I have a sneaky feeling PEEL are somehow involved.

As a market maker they don’t have to declare a holding until it’s above 10%

Always makes me smile when there is a tiny and insignificant website update undertaken, but hey its been a year in the making.

One page has had one minor change on the 1st Feb at 12.30pm.

Must have been a quiet lunchtime.